Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 14, 2019

SELL
$35.66 - $44.99 $99.8 Million - $126 Million
-2,799,916 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$36.57 - $47.97 $31.2 Million - $40.9 Million
-852,218 Reduced 23.33%
2,799,916 $122 Million
Q3 2018

Nov 14, 2018

SELL
$32.85 - $52.0 $3.34 Million - $5.29 Million
-101,700 Reduced 2.71%
3,652,134 $180 Million
Q2 2018

Aug 14, 2018

BUY
$27.5 - $39.8 $30.8 Million - $44.5 Million
1,118,918 Added 42.47%
3,753,834 $120 Million
Q1 2018

May 15, 2018

BUY
$29.98 - $46.35 $31 Million - $47.9 Million
1,032,582 Added 64.44%
2,634,916 $82.1 Million
Q4 2017

Feb 14, 2018

BUY
$31.85 - $46.95 $7.08 Million - $10.4 Million
222,200 Added 16.1%
1,602,334 $73.1 Million
Q3 2017

Nov 14, 2017

BUY
$35.7 - $39.5 $49.3 Million - $54.5 Million
1,380,134
1,380,134 $51.8 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Consonance Capital Management LP Portfolio

Follow Consonance Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Consonance Capital Management LP with notifications on news.